Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus

BILLERICA, Massachusetts ─  Bruker today announced that it has completed the acquisition of Phasefocus Holdings Limited, which was already announced on December 22nd, 2023.

Phasefocus is a privately held company that has leading expertise in imaging and image processing algorithms. Phasefocus has deployed their expertise to develop a novel optical microscope, called Livecyte, for label free imaging. Bruker’s global reach will help build on Phasefocus’ success to date.

Phasefocus’ microscopy capabilities will enhance Bruker’s existing portfolio, enabling new research advances in a range of cell imaging applications. This acquisition is another step forward in Bruker’s portfolio transformation.

Financial details of the transaction were not disclosed.

About Phasefocus

Based in Sheffield, UK, Phasefocus is a private company founded in 2006 from University of Sheffield research. Phasefocus is changing what is possible in live cell assays, helping scientists uncover subtle differences in cell behavior across whole cell populations. Livecyte, Phasefocus’s flagship product, delivers an unprecedented level of single cell data from live cells. High-contrast label-free imaging, correlative fluorescence and powerful automated image analysis algorithms result in high-content time-lapse outputs from standard 96-well plate assays.

About Bruker Corporation

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit:

< | >